Bisaro Paul reported grant involving 59,701 shares of MYRIAD GENETICS INC at $0.00 for $0 on Jun 4, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Jun 5, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
59,701Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
157,142Direct
Trade date
Jun 4, 2026Grant
Filed
Jun 5, 2026, 4:24 PM ET1-day reporting delay
Accession
0001237253-26-000004Code A · Transaction 99643
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

MYGN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MYGN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +10%1w ago −7.7%1d ago −3.7%
Returns since7d −5.3%30d +31%90d180d1y

Footnotes in full

F1: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.